The mAbs anti-HIV-1 p24-FITC (clone KC57), anti-Vα24-FITC (clone C15), and anti-Vβ11-PE (clone C21) were from Beckman Coulter, anti-CD1d-PE (clone CD1d42), anti-CD3 AF700 (clone UCHT1), anti-CD4 BV605 (clone RTA-T4), anti-CD11c-allophycocyanin (clone B-ly6), anti-CD11c PE-Cy5 (clone B-ly6), anti-CD45 PerCP (clone 2D1), anti-CD56 AF700 (clone B159), anti-CCR5 APC-Cy7 (clone 2D7/CCR5), anti-DC-SIGN v450 (clone DCN46) and anti-HLA-DR APC (clone L243) were from BD Biosciences (San Jose, CA, USA), anti-CD4 BV711 (clone OKT4) and anti-CD8 BV570 (clone RPA-T8) were from BioLegend (San Diego CA), anti-CD14 PE-Texas red was from Invitrogen, and anti-CD19 PE-Texas red (clone SJ25-C1) was from Abcam (Cambridge, UK). Data were acquired on a BD LSRFortessa instrument (BD Biosciences) and analyzed using FlowJo Version 9.7.5 software (TreeStar, Ashland, OR, USA). In some experiments, DCs were treated with 5 µg/ml Imiquimod (InvivoGen, Toulouse, France), 5 µg/ml Poly(I:C) (InvivoGen), 1 µg/ml ssRNA40LyoVec (Invivogen), 50 µM N-(n-Butyl)-deoxygalactojirimsin (NB-DGJ) (Toronto Research Chemicals, Toronto, Canada), 10 µM Chloroquine (InvivoGen), or with 5.6 µM TLR7 oligonucleotide antagonist IRS954: 5′-TGCTCCTGGAGGGGTTGT-3′ or the control oligo 5’-TCCTGCAGGTTAAGT-3 (Integrated DNA Technologies) (41 (link)).